| Sep 29 |
AbbVie: Dividend Discount Model Suggests Large Valuation Risks
|
| Sep 27 |
15 Unhealthiest Countries in Latin America
|
| Sep 27 |
Bristol Cobenfy approval draws optimism from Street, though with caveats
|
| Sep 27 |
ABBV's Newly Added Parkinson's Disease Drug Meets Second Study Goal
|
| Sep 27 |
AbbVie submits BLA for antibody-drug conjugate Teliso-V for NSCLC
|
| Sep 27 |
AbbVie Submits Biologics License Application to the FDA for Telisotuzumab Vedotin (Teliso-V) in Previously Treated Non-Small Cell Lung Cancer
|
| Sep 27 |
Bristol Myers Stock Up on FDA Nod for Schizophrenia Treatment
|
| Sep 27 |
Bristol Myers Stock Jumps. Why FDA Approval for Its Schizophrenia Drug Is Groundbreaking.
|
| Sep 27 |
AbbVie’s $8.7bn Parkinson’s disease drug shines in Phase III trial
|
| Sep 26 |
AbbVie Says Pivotal Trial For Parkinson's Candidate Meets Its Primary Goal In Patients With Early Disease
|
